Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2025-12-17 @ 8:46 AM
Study NCT ID:
NCT04655677
Status:
None
Last Update Posted:
2025-05-23 00:00:00
First Post:
2020-09-25 00:00:00
Brief Title:
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
Status:
None
Status Verified Date:
2025-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Baseline testing, Lymphodepleting, C-CAR039 infusion, and Follow-up Visit.
Detailed Description:
The study will include the following sequential phases Screening Apheresis Baseline Pre-Treatment Cell Product Preparation Lymphodepleting Chemotherapy EXP039 infusion and Follow-up Visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None